Small-Cap Premarket
November 9 Premarket, 09:08 ET: CKX, HRTX and INO Put Capital Structure First
Before the open: CKX’s billion-dollar investment, Heron’s asset sale and INOVIO’s offering put ownership, liabilities and new share supply at the center of the small-cap watchlist. Quotes through 09:08:28 ET.
Premarket briefing — November 9, 2026. Market-data cutoff: 09:08:28 a.m. Eastern Standard Time. Quotes below are individual observations between 09:07:41 and 09:08:28 ET, before the 09:30 regular-session open. November 9 is a regular trading day on the NYSE calendar, with the regular session scheduled to end at 16:00 ET.
Three small-cap situations stand out for their disclosed changes to capital or assets. CKX Lands has a proposed billion-dollar investment that would transform ownership. Heron Therapeutics has agreed to sell substantially all its assets while remaining public. INOVIO is approaching the expected closing of a large share offering. The common question is what each transaction leaves existing common shareholders owning.
Three names before the open
| Stock | Premarket observation | Displayed cumulative volume | Confirmed event | Capital question |
|---|---|---|---|---|
| CKX — CKX Lands | $17.27; +66.54%; 09:08:00 ET | 2,725,298 shares | Jacobs-led $1 billion investment agreement | Preferred conversion, warrants and a proposed reverse split reshape ownership. |
| HRTX — Heron Therapeutics | $0.3619; +23.52%; 09:08:28 ET | 84,246,243 shares | Agreement to sell substantially all assets to CorMedix | Consideration goes to Heron; it is not a stated cash payment per HRTX share. |
| INO — INOVIO Pharmaceuticals | $1.33; +9.47%; 09:07:41 ET | 2,409,190 shares | Priced offering expected to close November 9 | Separate common shares from pre-funded warrants and confirm closing. |
Source: linked FennEdge public research pages, observed before publication. Percentage changes are the feed's changes versus the previous regular close, not official opening gaps. Volume is the feed's cumulative share volume at each observation; it does not identify unique shares or net buying. These are selected event-driven names, not an exhaustive gainers ranking. Quotes may move before the open.
CKX: the investment headline needs the ownership terms
CKX's November 9 announcement says Jacobs Private Equity II and co-investors agreed to invest $1 billion. Brad Jacobs would become chairman and CEO after closing; the new platform's industry remains undecided. Completion is expected in early 2027, subject to shareholder approval and other conditions.
The proposed structure includes a 4.1744380-for-1 reverse split, preferred stock convertible into approximately 219 million post-split common shares, and warrants for approximately another 219 million. Those are potential shares under the transaction, not common shares already outstanding. The planned $20.8 million dividend is stated as $10.1312 per current share, with a record date shortly before closing. It is not an immediately payable distribution to today's buyers.
Before the open: distinguish today's pre-split quote from future post-split conversion and warrant terms. Comparing the current quote directly with a post-split exercise price would mix units. A billion-dollar investment commitment is not a billion-dollar valuation of today's common equity.
HRTX: an asset transaction, with a public company left behind
The joint company announcement specifies $145 million cash, subject to adjustments, plus 14,583,333 CorMedix shares for substantially all Heron assets. Up to $55 million in earn-outs and certain royalties are conditional. Closing is expected in the first quarter of 2027, subject to approvals and other conditions.
Heron is expected to remain publicly traded, with its credit facility repaid and a holding in CorMedix stock. Rubric's notes, about $37.8 million including accrued interest at September 30, are to be exchanged for some of that stock in four quarterly tranches after closing, subject to the agreement. That makes a simple headline-value-per-HRTX-share calculation inadequate. The fixed share consideration also carries exposure to CorMedix's market price; contingent payments are not cash already received. CorMedix's 8-K describes the agreement and assumed liabilities.
Before the open: establish what obligations, expenses and assets remain at Heron and whether any shareholder distribution is actually declared. The asset purchase does not itself establish an HRTX cash redemption price. The price advance and heavy turnover show attention; they do not resolve residual equity value.
INO: funding certainty and the enlarged share base
This follows our November 2 INO briefing, with financing now the specific focus. INOVIO's offering 8-K details 58,747,235 common shares at $1.05 and pre-funded warrants for 12,681,337 shares at $1.049 each, with a $0.001 exercise price. Underwriters exercised their option for 10,714,285 additional shares on November 6. Expected net proceeds including that option are approximately $80.5 million.
The filing expects closing on or about November 9, subject to conditions. That is an expected closing date, not confirmation that settlement has occurred. The package represents 82,142,857 common-share equivalents including the option and warrant underlying shares. That arithmetic does not mean every underlying warrant share has already been issued.
Before the open: check for a closing announcement and an updated outstanding-share count. The $1.33 observation is above the offering price, but an offering price is not a support guarantee. New funding and dilution can both matter to the same trade.
Size and supply: dated inputs, not a live pro forma cap table
| Stock | Vendor market cap, Nov. 6 | Shares outstanding shown by FennEdge | Reported float reference |
|---|---|---|---|
| CKX | $21.3 million | 2.05 million; Aug. 6 reference, 10-Q source | 1.28 million; Apr. 15, 2026 |
| HRTX | $55.1 million | 190.27 million; Nov. 4 reference, 10-Q source | 143.17 million; Aug. 14, 2026 |
| INO | $134.4 million | 103.40 million; Aug. 10 reference, 10-Q source | 101.81 million; Aug. 14, 2026 |
Market caps are dated vendor observations, not recalculations at the premarket quotes and not transaction-adjusted valuations. Float references are older vendor-reported share estimates shown by FennEdge; they are not current independently reconciled tradable supply. Outstanding shares and float have different definitions and dates. In particular, INO's August count predates the November offering, while CKX's historical capitalization cannot describe its proposed future ownership.
No complete current ATM, shelf-availability or warrant reconciliation was established for all three companies by this cutoff. Unknown capacity is not zero capacity, and an effective shelf alone would not prove shares were sold. At the open, the useful follow-up is fresh disclosure, executable spreads and how turnover develops around these specific events.
This article explains common concepts; examples are not trading recommendations.